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Abstract
Helicobacter pylori  (H. pylori ) infection is investigated 
in gastric diseases even during pregnancy. In particu-
lar, this Gram-negative bacterium seems to be associ-
ated with hyperemesis gravidarum, a severe form of 
nausea and vomiting during pregnancy. During the last 
decade, the relationship among H. pylori  and several 
extra-gastric diseases strongly emerged in literature. 
The correlation among H. pylori  infection and pregnan-
cy-related disorders was mainly focused on iron defi-
ciency anemia, thrombocytopenia, fetal malformations, 
miscarriage, pre-eclampsia and fetal growth restriction. 
H. pylori  infection may have a role in the pathogenesis 
of various pregnancy-related disorders through differ-
ent mechanisms: depletion of micronutrients (iron and 
vitamin B12) in maternal anemia and fetal neural tube 
defects; local or systemic induction of pro-inflamma-
tory cytokines release and oxidative stress in gastro-
intestinal disorders and pre-eclampsia; cross-reaction 
between specific anti-H. pylori  antibodies and antigens 
localized in placental tissue and endothelial cells (pre-
eclampsia, fetal growth restriction, miscarriage). Since 
H. pylori  infection is most likely acquired before preg-
nancy, it is widely believed that hormonal and immu-
nological changes occurring during pregnancy could 
activate latent H. pylori  with a negative impact not only 
on maternal health (nutritional deficiency, organ in-
jury, death), but also on the fetus (insufficient growth, 
malformation, death) and sometime consequences can 
be observed later in life. Another important issue ad-
dressed by investigators was to determine whether it 
is possible to transmit H. pylori  infection from mother 
to child and whether maternal anti-H. pylori  antibod-
ies could prevent infant’s infection. Studies on novel 
diagnostic and therapeutic methods for H. pylori  are 
no less important, since these are particularly sensitive 
topics in pregnancy conditions. It could be interest-
ing to study the possible correlation between H. pylori  
infection and other pregnancy-related diseases of un-
known etiology, such as gestational diabetes mellitus, 
obstetric cholestasis and spontaneous preterm delivery. 
Since H. pylori  infection is treatable, the demonstration 
of its causative role in pregnancy-related disorders will 
have important social-economic implications.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Helicobacter pylori  (H. pylori ) infection in 
pregnancy is not only associated with gastrointestinal 
disorders such as hyperemesis gravidarum, but also 
with iron deficiency anemia, fetal malformations, mis-
carriage, pre-eclampsia and fetal growth restriction. 
These pregnancy related-disorders are potentially life-
threatening for both mother and fetus/neonate. Anoth-
er important issue that has been addressed in literature 
was the question of whether it is possible to transmit 
H. pylori  infection from mother to child and whether 
maternal anti-H. pylori  antibodies could prevent infant’s 
infection. Indeed, if H. pylori  is actually a causal factor, 
the public health implications would be important since 
the infection is treatable.
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INTRODUCTION
Helicobacter pylori (H. pylori) infection affects approximate-
ly one half  of  the world population and it is more preva-
lent in developing countries[1,2]. This microorganism 
colonizes the stomach. Typically, it is acquired during 
childhood and causes asymptomatic chronic infection[2]. 
A small portion of  H. pylori infected subjects develop 
peptic ulcers and gastric carcinoma, usually during late 
adulthood[2].
H. pylori pathogenicity depends on several strain-spe-
cific factors. Some H. pylori strains express specific genes 
conferring pro-inflammatory, cytotoxic and vacuolating 
properties which could enhance the in vivo pathogenic-
ity[3]. Virulence factors such as urease and flagella are 
present in all strains and they are pivotal for pathogen-
esis and colonization[4]. Adhesins, such as Outer inflam-
matory protein and Sialic acid-binding adhesin, facilitate 
bacterial attachment to the host epithelium and often 
induce its inflammatory response[5,6]. H. pylori-strains can 
also express Cytotoxin-associated antigen A (CagA) and 
Vacuolating cytotoxin A (VacA), the most investigated 
cytotoxins among H. pylori virulence factors. CagA is 
directly injected into the cytoplasm of  epithelial cells, 
affecting cell morphology, proliferation and apoptosis[7]. 
H. pylori strains carrying CagA have been associated 
with both duodenal ulcer and gastric cancer[8], and infec-
tion with CagA-positive strain is generally associated to 
higher levels of  inflammatory mediators compared to 
CagA negative strains[3]. VacA is a proteic pore-forming 
toxin crucial to promote and maintain bacterial coloniza-
tion[9]. It disrupts cell polarity, promotes epithelial cells 
apoptosis and inhibits T cell proliferation and effector 
function[10]. Interestingly, combined seropositivity for 
both CagA and VacA directly correlates with elevated 
morbidity[11-13].
During the past decades, several reports indicated a 
correlation between H. pylori infection and various extra-
gastric disorders[14]. Such manifestations include ischemic 
heart disease, diabetes mellitus, idiopathic thrombocy-
topenia, urticaria, and sideropenic anemia[14]. Lanciers et 
al[15] (1999) found a significantly increased incidence of  
pregnant subjects with high H. pylori IgM (marker for 
recently acquired infection) compared to non pregnant 
women. These Authors suggested that pregnancy itself  
may increase the susceptibility to H. pylori infection[15]. 
This is probably due to the fact that there are immu-
nologic adaptations in pregnancy to ensure maternal 
tolerance towards the semi-allogeneic fetus. In general, 
pregnancy is characterized by a decreased cell-mediated 
cytotoxic immune response with preservation of  hu-
moral and innate immunity[16].
Nowadays, no follow-up study was conducted to de-
scribe the complete immune response against H. pylori 
infection during pregnancy. Most studies on the correla-
tion between H. pylori infection and pregnancy-related 
disorders were cross-sectional investigations where 
H. pylori positivity was detected during pregnancy or 
soon after delivery. H. pylori infection was tested before 
conception only in one prospective study, where early 
pregnancy loss was associated with maternal H. pylori 
CagA-strains seropositivity before intra-cytoplasmic 
sperm injection[17]. Indeed, it is not possible to definitely 
conclude whether pregnancy-related complications are 
correlated to H. pylori infection acquired before or dur-
ing pregnancy.
The prevalence of  H. pylori infection in pregnant 
women varies according to geographic area, socioeco-
nomic conditions and method used to detect H. pylori 
infection. For example, the prevalence of  H. pylori in-
fection among pregnant women is about 20%-30% in 
most European countries[18-20], Japan[21] and Australia[22], 
while it is 50%-70% in Turkey[23,24], Mexico and in Tex-
as, United States[25,26], more than 80% in Egypt[27] and 
Gambia[28]. Furthermore, inadequate sanitation prac-
tices, low social class and crowded or high-density living 
conditions seem to be related to a higher prevalence of  
H. pylori infection. These observations suggest that poor 
hygiene and crowded conditions may facilitate transmis-
sion of  infection among family members and they are 
consistent with data on intra-familial and institutional 
clustering of  H. pylori[29,30].
The first investigations on pregnancy focused their 
attention mainly on the relationship between hypereme-
sis gravidarum and H. pylori infection. Next, researchers 
turned their attention to other pregnancy-related disor-
ders, such as iron deficiency anemia, thrombocytopenia, 
fetal growth defects and malformations, miscarriage 
and, more recently, to pre-eclampsia. Another impor-
tant issue that has been addressed was the question 
of  whether it is possible to transmit H. pylori infection 
from mother to child and whether maternal anti-H. py-
lori antibodies could prevent infant’s infection. Finally, 
investigations on diagnostic and therapeutic methods 
for H. pylori are no less important, since they are par-
ticularly sensitive topics in pregnancy-related conditions. 
Herein, we reviewed the up-to-date literature about H. 
pylori and pregnancy.
GASTROINTESTINAL DISORDERS IN 
PREGNANCY
Mild to moderate dyspepsia is commonly associated 
with nausea and vomiting and complicates about 50% 
of  all pregnancies and it diminishes women’s life quality 
and social functions during early pregnancy[31]. In most 
women, these symptoms resolve by fluid and vitamin 
supplementation as well as dietary modification. About 
0.3%-2% of  pregnant women suffer from Hyperemesis 
Gravidarum (HG) characterized by severe and protract-
ed vomiting that often results in dehydration, electrolyte 
imbalance, ketonemia, ketonuria, and weight loss[31-34]. 
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Dehydration and acid base disturbances may lead to re-
nal and hepatic injury[35]. Patients who manifest continu-
ous weight loss and electrolyte disturbances may be at 
risk for growth restriction, fetal anomalies and decreased 
neonatal birth weight[36].
The onset of  gastrointestinal symptoms is always 
during the first trimester, but HG may persist through-
out gestation. The etiology of  HG, which still remains 
unknown, seems to be multifactorial and may be the final 
result of  various unrelated conditions. Indeed, treatment 
is performed on a symptomatic basis[35]. In particular, 
psychological causes, gastrointestinal tract dysfunctions, 
endocrine factors (i.e., elevated human chorionic go-
nadotropin and estrogen), genetic incompatibility, immu-
nological factors and nutritional deficiencies have been 
considered part of  the pathologic mechanism underlying 
HG. However, no single theory seems to provide an ad-
equate explanation for HG[33,35].
Significant positive association between HG and H. 
pylori infection has been demonstrated by several case-
control studies[37-42], and in a systematic review of  14 
case-control studies, Golberg et al[32] (2007) found higher 
prevalence of  HG in H. pylori-infected pregnant women 
than uninfected ones (pooled OR = 4.45; 95%CI: 
2.31-8.54). In contrast, most of  the studies aimed to de-
termine the link between H. pylori and dyspepsia failed to 
show a significant correlation between the clinical symp-
toms of  the disease and H. pylori infection[43,44]. Only 
two studies investigated the relationship between CagA-
positive H. pylori strains and gastrointestinal problems 
in pregnancy. Noyan et al[45] (2004) found a significant 
association between CagA-seropositivity and dyspepsia 
in pregnancy, though H. pylori-seroprevalence resulted 
slightly but not significantly higher in pregnant women 
with dyspeptic complaints (74.6%) compared to the 
controls (63.8%). Xia et al[46] (2004) demonstrated that 
the infection rates of  both H. pylori and CagA-positive 
strains are significantly higher in HG patients (88.9% 
and 78.1%, respectively) than in asymptomatic pregnant 
women (45.0% and 31.3%, respectively) (P < 0.01 for 
both).
Despite a high seropositive rate in pregnant women 
with severe gastrointestinal symptoms during early preg-
nancy, no correlation was found between seropositivity 
and clinical symptoms or their duration[47,48]. Shirin and 
colleagues (2004) reported an association between H. 
pylori and mild vomiting during early pregnancy but not 
with gastrointestinal symptoms later in pregnancy[49]. 
Studies performed on endoscopic biopsies of  gastric 
mucosa demonstrated that the severity of  gastrointesti-
nal symptoms in early pregnancy may be associated with 
the density of  H. pylori in the gastric epithelium[50]. Ad-
ditionally, two case reports showed that H. pylori eradica-
tion treatment reduces the severity of  HG[51,52].
In contrast, several studies found no relationship 
between HG and H. pylori[24,53-55]. These contradictory 
findings are probably due to the fact that a universally 
accepted HG definition does not exist, thus indicating a 
high heterogeneity of  the study population.
It has been proposed that a reduction of  gastric 
acid production during early pregnancy as a result of  
increased accumulation of  woman’s body fluid, steroid 
hormone changes, and immunologic tolerance could 
lead the activation of  latent H. pylori infection, which can 
exacerbate nausea and vomiting symptoms[42].
IRON DEFICIENCY ANEMIA
Iron deficiency is the most common nutritional defi-
ciency in the world and results in impairment of  im-
mune, cognitive and reproductive functions, as well as 
decreased work performance[56]. Iron deficiency anemia 
(IDA) affects more than a billion people worldwide and 
contributes to up to 40 percent of  maternal deaths in the 
developing countries[57]. In a typical singleton pregnancy, 
the average daily demand for iron is approximately 4.4 
mg. A supplementation is needed when diet alone can-
not supply this amount of  iron, but despite iron supple-
mentation, many women continue to remain anemic[58].
Muhsen et al[59] (2013) recommended the investiga-
tion of  H. pylori infection as a potential factor that might 
play a role in the occurrence of  anemia in children and 
pregnant women. Furthermore, eradication of  H. pylori 
infection has been recommended for patients with un-
explained IDA[60,61]. These recommendations are based 
on several studies that found a relationship between H. 
pylori and IDA. In a systematic review and meta-analysis 
of  12 case reports and series, 19 observational epide-
miologic studies and six interventional trials, Muhsen 
and Cohen (2008) found higher prevalence of  IDA in H. 
pylori-infected subjects than uninfected ones[62]. Several 
IDA mechanisms have been hypothesized in H. pylori 
infection, some of  which are decreased mucosal iron 
absorption capacity due to low gastric pH, reduction of  
stomach vitamin C levels, bacterium-host competition 
for dietary iron supply, lactoferrin mediated iron seques-
tration by gastric H. pylori, increased hepatocytes hep-
cidin release in response to IL-6 production associated 
with H. pylori gastritis[56,62-67].
In pregnant women, H. pylori infection has been found 
to be associated with IDA[19,68-70]. Weyermann et al[19] (2005) 
found lower haemoglobin (Hb) levels at the beginning 
of  pregnancy in H. pylori infected mothers vs noninfected 
(-0.25 g/dL; 95%CI: -0.49--0.003) and a more unfavour-
able change in Hb level during course of  pregnancy (-0.14 
g/dL; 95%CI: -0.38-0.10). In a cross-sectional study, out 
of  117 pregnant women, 27 had anemia and all of  the 
anemic patients were shown to be H. pylori infected, and 
with a high chance of  fetal growth restriction[68]. In a 
small prospective study aimed to confirm the association 
between H. pylori infection and HG, it was found that in-
fected pregnant women with HG have higher prevalence 
of  IDA compared to symptomatic uninfected patients[70]. 
In a small randomized double-blind placebo controlled 
trial, high prevalence of  H. pylori infection was seen in 
pregnant women suffering from IDA and eradication of  
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the infection by triple drug therapy during third trimester 
enhanced the response to oral iron folic acid supplemen-
tation[69].
PRE-ECLAMPSIA
Pre-eclampsia (PE) is a pregnancy-related syndrome 
characterized by new onset hypertension and proteinuria 
after 20 wk of  gestation in a previously normotensive 
woman. PE affects about 2%-8% of  all pregnancies and 
remains one of  the main causes of  either maternal or fe-
tal mortality and morbidity worldwide[71]. Despite PE has 
been object of  intense investigation, its etio-pathogenet-
ic mechanisms are still poorly understood. This difficulty 
is certainly due to the fact that PE is a syndrome where 
similar symptoms could origin from different pathogenic 
pathways. PE is characterized by a generalized vascular 
dysfunction and an excessive maternal inflammatory 
response. Furthermore, it is possible to recognize two 
different forms of  PE: “placental PE”, characterized by 
abnormal placentation and feto-placental compromise, 
and “maternal PE”, where etio-pathogenic mechanisms 
do not directly involve placenta and the fetus but they 
are of  exclusive maternal origin[72,73].
Several evidences suggest that subclinical infections 
could play a role in the onset of  PE[74,75]. The association 
between H. pylori seropositivity and PE was found for 
the first time by our group[76]. We showed that H. pylori 
seropositivity frequency is higher in mothers with PE 
(51.1%) compared with women with uneventful pregnan-
cy (31.9%) (OR = 2.67; 95%CI: 1.08-6.57; P = 0.033)[76]. 
Afterwards, other two case-control studies reported a 
significantly higher H. pylori seropositivity rate in PE 
patients compared to controls[77,78]. UstUn et al[77] (2010) 
reported a significantly higher positivity for IgA anti-H. 
pylori in patients with PE compared with controls (P = 
0.034), and Aksoy and colleagues found a H. pylori sero-
positivity rate of  81% in the pre-eclampsia group, and 
of  60% in normal pregnant women (OR = 2.86; 95%CI: 
1.05-7.82; P = 0.036)[78]. We also showed a strong as-
sociation between the onset of  PE and CagA-positive 
H. pylori strains infection, which are more virulent and 
therefore more likely to elicit the generalized inflam-
mation and the subsequent vascular damage typical of  
PE[76]. Recently, we found that CagA/VacA dual sero-
positivity is specifically associated with PE and, in par-
ticular, with “placental PE”[79]. Interestingly, Franceschi 
et al[80] (2012) demonstrated that antibodies against the H. 
pylori virulence factor CagA cross-react in vitro with pla-
cental tissue reducing its invasiveness ability and it is well 
known that these antibodies recognize antigens localized 
on the surface of  endothelial cells[81]. Therefore infection 
with CagA-positive strains could contribute not only to 
the exacerbated maternal inflammatory response leading 
to all forms of  PE but also to the abnormal placentation 
typical of  “placental PE”.
H. pylori could be involved in the pathogenesis of  PE 
mainly by inducing inflammation and oxidative stress 
and consequently generalized endothelial dysfunction. 
In fact, it was observed that H. pylori seropositive PE 
subjects are characterized by a more severe inflamma-
tory status compared to the inflammatory response 
characterizing normal pregnancy, since pre-eclamptic 
women showed higher levels of  C-reactive protein, 
tumour necrosis factor (TNF)-alpha and maternal leu-
kocytes counts[77,79]. Interestingly, pre-eclamptic patients, 
had higher H. pylori seropositivity rate and serum malo-
ndialdehyde levels, a common marker of  lipid peroxida-
tion, compared with healthy pregnant. Furthermore, the 
subgroup of  seropositive PE mothers had higher serum 
levels of  total cholesterol and low-density lipoprotein 
(LDL)-C compared to seronegative PE women. The 
Authors hypothesized that H. pylori infection may be a 
contributory factor in atherosclerosis in PE cases later in 
life[78]. Prospective cohort studies are required to confirm 
this hypothesis. However, such studies would be difficult 
to be conducted, since large cohorts of  pregnant women 
would be needed to detect significance and prospective 
studies are limited in their ability to evaluate uncommon 
outcomes such as PE.
FETAL GROWTH RESTRICTION
Fetal growth restriction (FGR) is defined as failure of  the 
fetus to achieve its genetically determined growth poten-
tial[82,83]. FGR may be due to either feto-placental or ma-
ternal causes and 3%-10% of  infants suffer from growth 
restriction. Feto-placental causes include infections and 
other placental pathologies. Known maternal causes of  
FGR include vascular disorders (chronic hypertension, 
pre-eclampsia or diabetes with vasculopathy), poor ma-
ternal weight gain, smoking, alcohol, cocaine, advanced 
maternal age and previous poor pregnancy outcome[84].
Eslick et al[22] (2002) observed for the first time an 
association between H. pylori infection and low birth 
weight, in particular they showed that intrauterine 
growth restriction was more common in H. pylori se-
ropositive women (13.5%) than in seronegative moth-
ers (6.0%) (OR = 2.41; 95%CI: 1.14-5.08; P = 0.018). 
Furthermore, it has been reported that H. pylori infected 
mice showed a decrease in implantation rates, and their 
offspring were of  low birth-weight[85]. However, in an-
other experimental mice model study these results were 
not confirmed[86].
H. pylori may be linked with an increase in symptoms 
including dyspepsia, nausea or vomiting[42,52], because of  
underlying undiagnosed peptic ulcer disease, which in 
turn may affect maternal gastric absorption and there-
fore impair fetal growth. Also maternal anemia associ-
ated to H. pylori infection may lead to FGR. In fact, Mu-
layim et al[68] (2008) observed that pregnant women with 
H. pylori infection delivered neonates with a significantly 
lower birth-weight compared to mothers without the 
infection. However, in this study FGR could be due to 
maternal anemia since all anemic pregnant women were 
in the H. pylori positive group. As previously underlined, 
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it was recently demonstrated that anti-CagA antibod-
ies cross-react in vitro with placental tissue reducing its 
invasiveness ability[80] and the consequent abnormal 
placentation could lead to FGR. However, in our study 
on H. pylori virulence factors we demonstrated a strong 
association between H. pylori infection and FGR in pre-
eclamptic pregnancies, while there was no association 
between H. pylori and idiopathic FGR[79].
OTHER PREGNANCY-RELATED 
DISORDERS
H. pylori infection has been linked to other few disease 
states in pregnancy but there are still small amount of  
data supporting these premises.
Miscarriage
Miscarriage or spontaneous abortion, occurring in 15% 
of  pregnancies, is defined as an unintended termina-
tion of  pregnancy resulting in fetal death prior to 23 wk 
of  gestation[87]. Among non-chromosomal causes of  
fetal loss, infections have a minor relevance compared 
to other etiologic factors. However Rossi et al[85] (2004) 
observed a higher number of  fetal resorption in H. py-
lori infected pregnant mice compared to non-infected 
controls. Hajishafiha et al[17] found an association be-
tween H. pylori CagA-strains maternal infection and early 
pregnancy loss in patients undergoing intra-cytoplasmic 
sperm injection. Recently we found a significantly higher 
percentage of  H. pylori seropositive women among pri-
migravidae with a miscarriage compared to controls, 
while the presence of  maternal serum antibodies against 
H. pylori did not appear to be associated with recurrent 
miscarriage[20]. These findings suggest a relationship be-
tween H. pylori infection and implantation/placentation 
failure, possibly due to a cross-reaction between antibod-
ies against H. pylori and placental tissue[80].
Neural tube defects
Several studies reported that serum/plasma vitamin 
B12 and folate levels are lower in subjects with H. pylori 
infection compared to uninfected persons[88,89]. More-
over, several investigations indicated that vitamin B12 
and folate levels improve after H. pylori eradication[90,91]. 
Two case-control studies in a Mexican-American and in 
Iranian population reported that H. pylori could play a 
role in neural tube defect (NTD) causation by reducing 
folate and vitamin B12 concentrations. They showed that 
H. pylori seropositivity in pregnant women can increase 
the risk of  occurrence of  NTDs in newborns, since se-
ropositivity was more frequent among mothers of  new-
borns with NTDs than controls[25,92]. However in both 
studies the differences were not significant.
Thrombocytopenia
Thrombocytopenia, although often innocuous[93], could 
have dangerous complications during pregnancy. Preg-
nancies affected by extremely low platelets, often with 
immune (idiopathic) thrombocytopenic purpura (ITP), 
require frequent careful monitoring during prenatal vis-
its, especially once entering the third trimester in prepa-
ration for delivery[94]. Furthermore, a recent retrospective 
study showed that ITP was an independent risk factor 
for both perinatal mortality and preterm delivery[95].
Association between H. pylori and thrombocytope-
nia has been demonstrated in a non-pregnant popula-
tion[96-98]. The etiology of  thrombocytopenia may be due 
to cross-molecular mimicry between specific H. pylori 
protein (CagA) and platelet antigens[99], however no rela-
tionship was found between H. pylori infection and plate-
let count during pregnancy[68,79,100,101].
It would be interesting to confirm the above men-
tioned findings and to investigate the possible correla-
tion among H. pylori infection and other pregnancy-
related diseases of  unknown etiology, such as gestational 
diabetes mellitus, obstetric cholestasis and spontaneous 
preterm delivery. In fact, H. pylori infection seems to be 
associated to diabetes mellitus[102] and hepatobiliary dis-
eases in the general population[103] and it is well known 
that bacterial infections increase the risk of  spontaneous 
preterm delivery[104].
MOTHER-TO-CHILD TRANSMISSION
Children of  H. pylori infected mothers seem to have 
a higher risk of  acquiring H. pylori[27,105]. However, ex-
perimental animal models suggested that vertical infec-
tion during the prenatal period or delivery procedure 
is unlikely to be route of  mother-to-child transmission 
of  the infection. It is possible that H. pylori is acquired 
through breast-feeding, contaminated saliva and fecal-
oral transmission during co-habitation[21,86,106]. Indeed, 
for the general population, the most common way of  
transmission is from person to person by either oral-oral 
route (through vomitus or possibly saliva) or fecal-oral 
route. The person-to-person way of  transmission is sup-
ported by the higher incidence of  infection among insti-
tutionalized children and adults and the clustering of  H. 
pylori infection within families. Moreover, detection of  H. 
pylori DNA in vomitus, saliva, dental plaque, gastric juice, 
and feces further supports this concept. Waterborne 
transmission, probably due to fecal contamination, may 
be an important source of  infection, especially in those 
world’s areas in which untreated water is common[29,30].
Furthermore, in our previous study on pre-eclampsia 
and H. pylori we indirectly demonstrated the absence of  
vertical transmission in humans, since we never found 
the presence of  H. pylori DNA in placentae of  H. pylori 
positive patients[76].
It is widely established that specific anti-H. pylori IgG 
antibodies are transplacentally transferred from moth-
ers to fetuses[18] and a close correlation between mater-
nal and cord specific IgG levels was demonstrated[21,28]. 
These passively acquired antibodies decline over the first 
3-4 mo of  life[18,28]. Some researchers have suggested 
that maternal IgG may protect against H. pylori colo-
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nization[18,107] and this is supported by work in murine 
models[108]. Other investigators found no evidence of  a 
protective role for passively acquired maternal antibodies 
in infants at high risk of  early H. pylori colonization[28].
It was also suggested that IgA antibodies in maternal 
milk confer passive protection against early human H. 
pylori colonization[109-111]. However, in a previous study 
the relationship between breastfeeding and H. pylori was 
investigated in 946 preschool children and their mothers 
with C-urea breath test. H. pylori prevalence was higher 
in breastfed children compared with children who were 
never breastfed. The Authors concluded that breastfeed-
ing was not protective against H. pylori[112].
H. PYLORI INFECTION DIAGNOSIS 
DURING PREGNANCY
The current diagnostic methods include invasive and 
non-invasive tests. Invasive tests involve an upper gas-
trointestinal endoscopy with gastric mucosal biopsy and 
rapid urease activity detection, histology, microbiological 
culture, or polymerase chain reaction assays. Although 
mucosal biopsy and histopathologic examination of  
specimens for the presence of  H. pylori and/or gastritis 
is considered the gold standard for the diagnosis of  H. 
pylori infection, invasive tests are not well tolerated by pa-
tients and may be a source of  ethical problems. Gastros-
copy can be performed in pregnant patients, but only 
when it is strictly necessary[113].
The non invasive methods are more widely accepted 
in the prenatal period and include serum antibody detec-
tion, carbon-labeled urea breath tests, and stool antigen 
detection.
Serologic and stool antigen tests are the first choice 
for H. pylori infection diagnosis in pregnancy, since they 
are easy to perform and low-cost non invasive diagnostic 
tests. Serologic tests are usually based on the detection 
of  specific anti-H. pylori IgG antibodies in the patients’ 
sera by immuno-enzymatic assay. Measurement of  IgG 
antibodies against H. pylori reveals an immune response 
that could represent either a current infection or a previ-
ous exposure, since IgG antibodies disappear only sev-
eral months after eradication of  the microorganism[114].
The stool antigen test is an enzymatic immunoassay 
that detects the active presence of  H. pylori antigen in 
human feces. Stool antigen test is preferred to determine 
the H. pylori status after eradication[115].
Urea breath tests are not commonly used during 
pregnancy, despite they are reliable and noninvasive 
diagnostic test. In fact, it is demonstrated that 13C-urea 
breath test, using the stable isotope 13C as tracer, is not 
radioactive and safe also in children and pregnancy. 
Therefore, it could be used as a valuable non-invasive 
semi-quantitative diagnostic tool for the assessment of  
gastric bacterial H. pylori infection. The urea breath test 
is recommended for test-and-treat strategies and suitable 
for control after eradication therapy and in epidemiolog-
ical or pharmacological studies[116]. Despite the excellent 
sensitivity and specificity of  these tests, they are expen-
sive and require specific instrumentation and specialized 
staff.
Furthermore, it was stated that ionizing radiation 
dose involved in 14C-urea breath test is extremely low, 
much lower than the radiation dose adsorbed from natu-
ral sources, a thousand times lower than the amount of  
fetal radiation considered to be teratogenic, therefore in 
the event of  inadvertent exposure during pregnancy, the 
pregnant women should be reassured[117].
H. PYLORI INFECTION TREATMENT 
DURING PREGNANCY
There are multiple options for H. pylori infection treat-
ment. The association of  a proton-pump inhibitor and 
two antibiotics for 1 or 2 wk gives the best eradication 
rates in non pregnant subjects. Currently, there are no 
guidelines to treat H. pylori infection during pregnancy 
and the optimal therapy in pregnancy remains uncer-
tain[118]. Hayakawa et al[119] treated four women with hy-
peremesis gravidarum by a combination of  penicillin and 
erythromycin, leading to alleviation of  symptoms thus 
demonstrating the possible effectiveness of  this specific 
H. pylori treatment. This hypothesis is supported in four 
additional case reports that showed similar symptom re-
lief  after antibiotic treatment[47,51,52,120].
Several investigators have evaluated the safety of  in-
dividual drugs, including proton pump inhibitors used in 
the anti H. pylori drug therapy in pregnant women. A re-
cent meta-analysis reported that the use of  proton pump 
inhibitors during first-trimester does not seem to be 
associated with increased risk of  spontaneous abortion, 
preterm delivery or major congenital birth defects[121]. 
Nevertheless, some experts recommend that H. pylori 
eradication should be deferred until after pregnancy and 
lactation[122].
It must be considered that treatment of  H. pylori 
infection has a low successful rate, with 35%-85% of  
infections being cleared, reaching the lowest values in 
some European countries[123]. The gradual but steady oc-
currence of  antibiotic-resistant strains represents a major 
obstacle in the treatment of  H. pylori infection. Pharma-
cogenomics-based approaches seem to increase the cure 
rates, but re-infection also remains problematic. In fact, 
it is well known that eradication of  H. pylori infections 
with antimicrobial agents in adults does not induce im-
munity against re-infection. In general, low annual recur-
rence rates were observed in developed countries (up to 
2% for both adults and children), but high recurrence 
rates (> 10%) were observed in developing countries[124]. 
There is no clear evidence that pregnancy predisposes to 
de novo H. pylori infection.
In view of  these evidences, new approaches need 
to be considered for treatment of  this disease, such as 
design of  effective vaccines. Especially in case of  preg-
nancy related diseases, it would be preferable to prevent 
H. pylori infection consequences, thus avoiding phar-
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macologic therapies during pregnancy. Recently, several 
clinical trials and animal studies have been focused on 
generating H. pylori recombinant vaccines useful to eradi-
cate and protect against the infection; however a safe and 
effective H. pylori vaccine has not yet been developed for 
use in humans[123].
Therefore, if  H. pylori infection will be confirmed as 
an important risk factor for pregnancy complications, 
we suggest the conventional H. pylori eradication, namely 
triple therapy, should ideally be obtained several months 
before conception in order to reach seronegativity. This 
approach would avoid cross-reaction between anti-H. 
pylori antibodies and host tissue antigens, waiting for the 
discovery of  novel effective vaccines.
CONCLUSION
H. pylori infection was investigated not only in associa-
tion with gastrointestinal manifestations during pregnan-
cy but also with other severe pregnancy-related disorders. 
H. pylori infection may have a role in the pathogenesis 
of  these disorders through different mechanisms: deple-
tion of  micronutrients (iron and vitamin B12) in the case 
of  maternal anemia and fetal neural tube defects; local 
and systemic induction of  pro-inflammatory cytokines 
release and oxidative stress in gastrointestinal disorders 
and pre-eclampsia; cross-reaction between specific an-
ti-H. pylori antibodies and antigens localized in placental 
and endothelial cells (pre-eclampsia, fetal growth restric-
tion, miscarriage) (Figure 1). Since H. pylori infection is 
most likely acquired before pregnancy, it is believed that 
hormonal and immunological changes occurring dur-
ing pregnancy can activate latent H. pylori infection and 
this could have an impact not only on the mother health 
(nutritional deficiency, organ injury, death), but also on 
her child (insufficient growth, malformation, death) and 
sometime consequences can be observed later in life.
H. pylori mother to child transmission does not ap-
pear to occur during pregnancy or delivery. Furthermore, 
it was demonstrated that specific antibodies against this 
microorganism are transferred to the fetus/infant both 
transplacentally and by means of  maternal milk. How-
ever, it is not clear whether maternal antibodies are able 
to protect the children against H. pylori colonization.
Currently, clinicians choose a non-invasive diagnostic 
method for H. pylori infection and prefer to treat the in-
fection out of  pregnancy. If  H. pylori will be confirmed 
as causal and/or contributing factor of  major pregnan-

























Figure 1  Helicobacter pylori infection correlation with pregnancy-related disorders. Helicobacter pylori (H. pylori) infection can cause local damage and inflam-
mation, leading to gastrointestinal disorders such as dyspepsia in pregnancy and hyperemesis gravidarum. H. pylori sequesters essential micronutrients from the host 
organism. In particular, iron depletion may lead to iron deficiency anemia (IDA), while reduction of vitamin B12 and folate may result in fetal neural tube defects. Lack 
of these micronutrients may also be favored by gastric malabsorption in case of the above mentioned gastrointestinal problems. Furthermore, IDA could indirectly be 
the consequence of local and systemic inflammation induced by H. pylori infection. Finally, the immune and inflammatory responses caused by this infection lead to 
endothelial and placental injury, through the cross-reaction of anti-H. pylori and tissue antigens and through the production of pro-inflammatory cytokines. Placental 
dysfunction characterizes important diseases of pregnancy, such as miscarriage, fetal growth restriction (FGR) and pre-eclampsia that it is also characterized by en-
dothelial damage and it is often associated with FGR. Furthermore, IDA could be a risk factor for FGR.
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cy-related disorders, it will have important positive impli-
cations for the public health system since the infection 
is treatable. It is likely that pre-pregnancy diagnosis and 
preventive H. pylori eradication would reduce the inci-
dence of  some of  these complications. More data are 
needed to understand if  screening for H. pylori infection 
could be effective in preventing pregnancy disorders. 
The design of  an effective vaccine will be even more 
useful in order to avoid drug resistance and re-infection 
problems. 
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